RGEN logo

REPLIGEN CORP

RGENNASDAQ
πŸ† #834 by market capEarnings Nov 3US Equity
$194.57β–² $0.49 (+0.25%)
πŸŒ™ After hours$194.57β–² 0.00%Regular close Β· extended-hours price shown
πŸ””
Track RGEN
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 0.3%
7dβ–² 4.2%
14dβ–² 11.4%
30dβ–² 10.4%
ytdβ–² 18.7%
1yβ–² 56.7%
🏦Market Cap
$10.98B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
+16.4%
Healthy
πŸ“ŠGross Margin
51.0%
Healthy
πŸ’΅FCF Margin
14.1%
Healthy
βš–οΈP/S Ratio
14.0x
Elevated
Otter Score
92
Very Good

Trading Snapshot

Day Range
$192.49 – $195.84
52-Week Range
$100.99 – $198.87
Volume
$1.64B
Avg Volume
$1.88B
Shares Outstanding
56.4M
Next Earnings
Nov 2, 2026

Fundamentals Snapshot

Annual Revenue
$738M
Last Q Revenue
$204M
P/E Ratio
262.3
P/S Ratio
14.0x
EPS (TTM)
$0.74
Dividend Yield
0.00%
Dilution (1yr)
+0.8%

Why Investors Own RGEN

  • βœ“High-growth profile β€” revenue up +36.2% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 63% gross margin and 8% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

RGEN logo

REPLIGEN CORP

RGEN
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$738Mβ–² +16.4% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
47.1%β–² +8.8% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$60Mβ–Ό βˆ’269.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$94Mβ–Ό βˆ’34.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
56.5Mβ–² +0.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$124Mβ–Ό βˆ’$195M YoY
StockOtter Β· stockotter.space

About REPLIGEN CORP

Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Very Good
92/100

Analyst Price Target

β“˜
Average Target
$204.64
β–² +5.2% Upside
High Target$221.81
Low Target$162.72
Based on 38 analysts

Latest News & Updates

Defense WorldΒ·4d ago

Repligen (NASDAQ:RGEN) Hits New 52-Week High – Still a Buy?

Repligen Corporation (NASDAQ: RGEN - Get Free Report) reached a new 52-week high on Wednesday. The stock traded as high as $188.95 and last traded at $186.9330, with a volume of 25119 shares traded. The stock had previou

Defense WorldΒ·10d ago

Tidal Investments LLC Raises Holdings in Repligen Corporation $RGEN

Tidal Investments LLC increased its stake in shares of Repligen Corporation (NASDAQ: RGEN) by 75.2% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Co

Business WireΒ·19d ago

BioLife Solutions Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioLife Solutions, Inc. - BLFS

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (β€œKSF”) are investigating the proposed sale of BioLife Solutions, Inc. (

Seeking AlphaΒ·20d ago

Repligen Corporation (RGEN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Repligen Corporation (RGEN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Zacks Investment ResearchΒ·Aug 27

Why Is Repligen (RGEN) Up 27.7% Since Last Earnings Report?

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?

Zacks Investment ResearchΒ·Aug 27

Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen

Halozyme, Repligen, Iovance, Arcutis and Precigen have been highlighted in this Industry Outlook article.